PL1748781T3 - Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów - Google Patents

Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów

Info

Publication number
PL1748781T3
PL1748781T3 PL05765950T PL05765950T PL1748781T3 PL 1748781 T3 PL1748781 T3 PL 1748781T3 PL 05765950 T PL05765950 T PL 05765950T PL 05765950 T PL05765950 T PL 05765950T PL 1748781 T3 PL1748781 T3 PL 1748781T3
Authority
PL
Poland
Prior art keywords
methods
sulfated polysaccharides
bleeding disorders
treating bleeding
treating
Prior art date
Application number
PL05765950T
Other languages
English (en)
Inventor
Kirk W Johnson
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of PL1748781T3 publication Critical patent/PL1748781T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05765950T 2004-05-27 2005-05-27 Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów PL1748781T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides
EP05765950A EP1748781B1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
PL1748781T3 true PL1748781T3 (pl) 2013-05-31

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05765950T PL1748781T3 (pl) 2004-05-27 2005-05-27 Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów

Country Status (15)

Country Link
US (4) US7767654B2 (pl)
EP (2) EP2165711B1 (pl)
JP (2) JP5232470B2 (pl)
CN (2) CN1984664B (pl)
AU (1) AU2005249465B2 (pl)
BR (1) BRPI0511603A (pl)
CA (1) CA2567495C (pl)
CY (1) CY1113705T1 (pl)
DK (1) DK1748781T3 (pl)
ES (2) ES2399277T3 (pl)
PL (1) PL1748781T3 (pl)
PT (1) PT1748781E (pl)
RU (1) RU2347574C2 (pl)
SI (1) SI1748781T1 (pl)
WO (1) WO2005117912A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL1748781T3 (pl) * 2004-05-27 2013-05-31 Baxter Int Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
CA2648533A1 (en) * 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides
ES2683948T3 (es) * 2007-02-23 2018-09-28 Baxalta GmbH Métodos de procedimiento para la purificación de fucoidano a partir de extractos de algas marinas
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
WO2010020423A2 (en) * 2008-08-22 2010-02-25 Baxter Healthcare S.A. Methods for treating bleeding disorders
EP2358402A2 (en) * 2008-12-11 2011-08-24 Baxter International Inc. Preparations based on fibrinogen and sulfated polysaccharides
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
AU2011205271B2 (en) * 2010-01-14 2014-01-30 Baxalta GmbH Methods and compositions for treating bleeding disorders
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
AU2011244348B2 (en) * 2010-04-20 2015-02-12 Octapharma Ag New stabilizing agent for pharmaceutical proteins
CA2812888A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
EP2734213B1 (en) * 2011-07-19 2018-06-06 Baxalta GmbH Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
ES2699238T3 (es) * 2012-01-30 2019-02-08 Baxalta GmbH Polisacáridos sulfatados o sulfonatados no anticoagulantes
JP6138829B2 (ja) * 2012-01-30 2017-05-31 バクスアルタ ゲーエムベーハー 非抗凝固性の硫酸化またはスルホン酸化合成ポリマー
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
DK2885642T3 (da) 2012-08-14 2019-07-29 Baxalta GmbH Fremgangsmåder og systemer til screening af sammensætninger omfattende ikke-antikoagulerende sulfaterede polysaccharider
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
WO2018043666A1 (ja) * 2016-08-31 2018-03-08 王子ホールディングス株式会社 酸性キシロオリゴ糖の製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
EP3632451A4 (en) 2017-05-31 2021-03-10 Oji Holdings Corporation MOISTURIZING TOPICAL PREPARATION
WO2019054344A1 (ja) 2017-09-12 2019-03-21 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法
AU2018387999B2 (en) 2017-12-20 2021-06-17 Oji Holdings Corporation Pentosan polysulfate and medicine containing pentosan polysulfate
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
WO1992007954A1 (en) * 1990-11-05 1992-05-14 Baxter Diagnostics Inc. A method to determine the concentration of anticoagulants
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
DE69637747D1 (de) * 1995-04-28 2008-12-24 Res Inst For Glycotechnology H Zuckerverbindungen
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
EP0977995B1 (de) * 1997-04-25 2005-03-02 Pentapharm AG Verfahren zum funktionellen nachweis von störungen im protein c-system
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR100727339B1 (ko) * 1999-04-15 2007-06-12 다카라 바이오 가부시키가이샤 치료제
EP1279405A1 (en) * 2000-03-30 2003-01-29 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
EP1359936B1 (en) * 2001-02-05 2008-02-20 Novo Nordisk Health Care AG Combined use of factor vii polypeptides and factor viii polypeptides
DE60202427T2 (de) * 2001-10-24 2005-12-29 Takara Bio Inc., Otsu Sulfatiertes Fucan-Oligosaccharid
JP3941036B2 (ja) * 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
EP1644416A4 (en) * 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
PL1748781T3 (pl) * 2004-05-27 2013-05-31 Baxter Int Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
CA2648533A1 (en) 2006-04-27 2007-11-08 Avigen, Inc. Method for treating thrombotic disorders using sulfated polysaccharides

Also Published As

Publication number Publication date
HK1142276A1 (en) 2010-12-03
CN1984664A (zh) 2007-06-20
US20050282771A1 (en) 2005-12-22
DK1748781T3 (da) 2013-02-11
US20110237512A1 (en) 2011-09-29
CA2567495C (en) 2014-02-18
RU2347574C2 (ru) 2009-02-27
JP2008500367A (ja) 2008-01-10
US20120129777A1 (en) 2012-05-24
EP2165711B1 (en) 2014-05-21
US7767654B2 (en) 2010-08-03
CA2567495A1 (en) 2005-12-15
EP1748781B1 (en) 2012-12-19
EP1748781A4 (en) 2008-07-02
AU2005249465B2 (en) 2007-12-06
US8771973B2 (en) 2014-07-08
WO2005117912A1 (en) 2005-12-15
JP5232470B2 (ja) 2013-07-10
CY1113705T1 (el) 2016-06-22
SI1748781T1 (sl) 2013-03-29
RU2006146801A (ru) 2008-07-10
ES2482105T3 (es) 2014-08-01
US7829549B2 (en) 2010-11-09
BRPI0511603A (pt) 2008-01-02
CN1984664B (zh) 2013-07-24
HK1103624A1 (en) 2007-12-28
EP2165711A1 (en) 2010-03-24
AU2005249465A1 (en) 2005-12-15
US8859526B2 (en) 2014-10-14
US20090269325A1 (en) 2009-10-29
CN103251647A (zh) 2013-08-21
PT1748781E (pt) 2013-01-22
EP1748781A1 (en) 2007-02-07
ES2399277T3 (es) 2013-03-27
JP2012046551A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
PL1748781T3 (pl) Sposoby do leczenia zaburzeń związanych z krwawieniem z zastosowaniem siarczanowanych polisacharydów
EP1855710A4 (en) MUSCLE REGENERATION
IL183985A0 (en) Methods for treating autoimmune disorders
IL183889A0 (en) Treatment method
IL186408A0 (en) Combination treatment methods
PL1805312T3 (pl) Sposoby i środki do wytwarzania hialuronianu
IL187450A0 (en) Methods for treating fibrotic conditions
IL182011A0 (en) Treatment screening methods
GB0526291D0 (en) Therapeutic method
EP1797020A4 (en) GUANIDINE POLYSACCHARIDES, THEIR USE AS ABSORBENTS AND PROCESS FOR THE PRODUCTION THEREOF
EP1912658A4 (en) THERAPEUTIC PROTOCOLS WITH HYALURONANE
GB0525957D0 (en) Methods
EP1883405A4 (en) METHODS OF TREATING NEPHROLITHIASIS
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
PT1686201E (pt) Aparelho de pulling-down
IL188127A0 (en) Methods for treating demyelination disorders
GB0715741D0 (en) Methods
GB0518232D0 (en) New methods
GB0502171D0 (en) Well treatment
GB0518425D0 (en) Methods
EP1928498A4 (en) METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
ZA200709915B (en) Methods for treating fibrotic conditions
GB0514661D0 (en) Methods
GB0516204D0 (en) Methods